Showing results (441-450 of 16,802) with videos related to
Sort By:
Pageof 1,681
British Journal of Haematology|February 1, 1992
The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic studyJ Cebon, G J Lieschke, R W Bury, et al.British Journal of Haematology|February 1, 1992
Increase in 2',5'-oligoadenylate synthetase caused by deoxycoformycin in hairy cell leukaemiaK Ganeshaguru, W C de Mel, G Sissolak, et al.British Journal of Haematology|February 1, 1992
VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)M Monconduit, J F Menard, J L Michaux, et al.British Journal of Haematology|February 1, 1992
Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytesA Djeha, J H BrockBritish Journal of Haematology|November 4, 2004
Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survivalAttaya Suvannasankha, Hans Minderman, Kieran L O'Loughlin, et al.British Journal of Haematology|November 4, 2004
T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experienceH Y Draoua, Lawrence Tsao, Donna M Mancini, et al.British Journal of Haematology|November 4, 2004
TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarctionHiroyasu Akatsu, Hidehisa Yamagata, Yusen Chen, et al.British Journal of Haematology|November 4, 2004
Clonogenicity, gene expression and phenotype during neutrophil versus erythroid differentiation of cytokine-stimulated CD34+ human marrow cells in vitroLouise Edvardsson, Josefina Dykes, Martin L Olsson, et al.British Journal of Haematology|November 4, 2004
CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attackArnon P Kater, Ludo M Evers, Ester B M Remmerswaal, et al.British Journal of Haematology|June 15, 2005
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaHeather E Oakervee, Rakesh Popat, Nicola Curry, et al.Pageof 1,681